CIENCIASMEDICASNEWS: Antibody Screening Tools; Improving Workflows

miércoles, 24 de octubre de 2018

Antibody Screening Tools; Improving Workflows

	October 24, 2018
	Immunology
	The latest immunology news from News Medical

Antibody Screening Tools; Improving Workflows

New therapeutic antibodies are constantly needed for immunotherapies, Thomas Duensing from Intellicyt, Part of the Sartorius Group discusses how the Intellicyt® iQue Screener Plus platform enables multiplexed antibody screening, which increases the rate that these screens can be performed to thousands per hour.

Live-Cell Analysis Handbook, 2nd Edition!

Real-time live-cell analysis is redefining the possibilities and workflows of cell biology. The combination of ease of use, throughput, and non-invasive measurement enables researchers to monitor and measure cell behaviors at a scale and in ways that were previously not possible.

Download the Handbook to learn more

Researchers discover previously unknown function of key component in the immune system

The complement proteins that circulate in our blood are an important part of our immune system. They help identify bacteria, viruses and other harmful organisms, making it easier for our white blood cells to find and neutralize dangerous microbes.

	What are PARP inhibitors? Poly ADP-ribose polymerase (PARP) inhibitors are pharmaceutical drugs that can be used to treat many different forms of cancer, including ovarian and breast cancer. They manipulate DNA repair pathways, causing the death of cancerous cells.

	'Supercharged' immune cells could help fight cancer A type of 'supercharged' immune cell could be mass-produced to help fight cancer. The researchers behind the early-stage finding, from Imperial College London, say the development could mark the next generation of cutting-edge immunotherapy treatments, called CAR-T therapies.

	A Single Platform to Sequence All Monoclonal Antibody Proteins Primary sequences of antibody proteins are one of the important pieces of information researchers need to know at an early stage of the antibody drug discovery, research and development process.